The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

111 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.EBI
Abbvie
Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries.EBI
Abbvie
Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8.EBI
Abbvie
Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.EBI
Abbvie
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.EBI
Abbvie
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.EBI
Abbvie
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.EBI
Abbvie
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.EBI
Abbvie
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.EBI
Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.EBI
Abbvie
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.EBI
Abbvie
Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.EBI
Abbvie
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.EBI
Abbvie
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.EBI
Abbvie
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.EBI
AbbVie
Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.EBI
Abbvie
Pipeline Impact of Radiolabeled Compounds in Drug Discovery and Development.EBI
Abbvie
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule NaEBI
Abbvie
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.EBI
Abbvie
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.EBI
Abbvie
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.EBI
Abbvie
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor.EBI
Abbvie
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XEBI
Abbvie
Structure-Based Design of A-1293102, a Potent and Selective BCL-XEBI
Abbvie
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.EBI
Abbvie
Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.EBI
Abbvie
Discovery of EBI
Abbvie
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.EBI
Abbvie
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.EBI
Abbvie
Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.EBI
Abbvie
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.EBI
Abbvie
Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.EBI
Abbvie
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.EBI
Abbvie
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.EBI
Abbvie
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).EBI
Abbvie
De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.EBI
Abbvie
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.EBI
Abbvie
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.EBI
Abbvie
Methylpyrrole inhibitors of BET bromodomains.EBI
Abbvie
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).EBI
Abbvie
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.EBI
Abbvie
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.EBI
Abbvie
Substituted quinazolines as HDAC6 inhibitorsBDB
Augustine Therapeutics
Covalent inhibitors of coronavirus papain-like proteaseBDB
UT-Battelle
Disubstituted Pyrimidine Compounds for Ketohexokinase InhibitionBDB
Centennial Therapeutics
FUSED RING DERIVATIVES CONTAINING 1,4-OXAZEPANEBDB
Medshine Discovery
THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCERBDB
National Cancer Center
COMPOUNDS FOR TREATING CERTAIN LEUKEMIASBDB
Terns Pharmaceuticals
ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOFBDB
Bolt Biotherapeutics
ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERSBDB
University of Mississippi
TKI permeability enhancersBDB
City of Hope
Spiropyrrolidine derived antiviral agentsBDB
Enanta Pharmaceuticals
Methotrexate adjuvants to reduce toxicity and methods for using the sameBDB
Tosk
Salts and pharmaceutical compositions thereof for the treatment of inflammatory disordersBDB
Galapagos
Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereofBDB
Chia Tai Tianqing Pharmaceutical Group
2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitorsBDB
H. Lundbeck
Inhibitors of protease-activated receptor-2BDB
Heptares Therapeutics
Macrocyclic indole derivatives useful as hepatitis C virus inhibitorsBDB
Janssen Ireland
Compounds inhibiting leucine-rich repeat kinase enzyme activityBDB
Merck Sharp & Dohme
Heterocyclic modulators of cannabinoid receptorsBDB
The Cleveland Clinic Foundation
Slowly on, Slowly off: Bisubstrate-Analogue Conjugates of 5-Iodotubercidin and Histone H3 Peptide Targeting Protein Kinase Haspin.BDB
University of Tartu
1,3-dioxanomorphides and 1,3-dioxanocodidesBDB
Rhodes Technologies
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesBDB
Almirall
2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereofBDB
Georgetown University
Bromodomain inhibitorsBDB
Abbvie
Therapeutic compoundsBDB
Regents of The University of Minnesota
Sulfonamide compoundsBDB
Kancera
Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitorsBDB
Nerviano Medical Sciences
Morpholine compounds and uses thereofBDB
Hoffmann-La Roche
Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitorsBDB
Novartis
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.BDB
University College London
Compounds for inhibiting the interaction of BCL2 with binding partnersBDB
Novartis
BenzamidesBDB
H. Lundbeck
Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives.BDB
Bezmialem Vakif University
Anticancer compoundsBDB
Boehringer Ingelheim International
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylaseBDB
Fibrogen
Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compoundsBDB
Array Biopharma
Organic compoundsBDB
Novartis
Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitorsBDB
Merck Sharp & Dohme
Compounds and compositions as protein kinase inhibitorsBDB
TBA
Trisubstituted purine derivativesBDB
Cyclacel
Triazole compounds as KSP inhibitorsBDB
Novartis
InhibitorsBDB
Probiodrug
Inhibitors of protein kinasesBDB
Portola Pharmaceuticals
Heteroaryloxyheterocyclyl compounds as PDE10 inhibitorsBDB
Amgen
Role of the four conserved histidine residues in the amidotransferase domain of carbamoyl phosphate synthetase.BDB
Texas A&M University
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.BDB
National Yang-Ming University
Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors.BDB
Korea Research Institute of Chemical Technology
Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin.BDB
University of Tokyo
Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.BDB
Schering-Plough Research Institute
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.BDB
Harvard University
In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.BDB
Merck Research Laboratories
L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.BDB
Case Western Reserve University
Identification of a novel human eicosanoid receptor coupled to G(i/o).BDB
Tanabe Seiyaku
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.BDB
University of Oslo
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.BDB
Sri International
A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.BDB
The University of Tokyo
YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.BDB
Yamanouchi Pharmaceutical
Structural combination of established 5-HT(2A) receptor ligands: new aspects of the binding mode.BDB
University of Mainz
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.BDB
Eli Lilly
Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain.BDB
UniversitÉ
Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.BDB
Universita Degli Studi Di Firenze
Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.BDB
Niigata College of Pharmacy
SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum.BDB
Sandoz Pharma
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.BDB
University of New Mexico
Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.BDB
TBA
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.BDB
University of Luxembourg